Carbamazepine, HLA-B1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA...
Carbamazepine, HLA-B1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations
About this item
Full title
Author / Creator
Publisher
England: Future Medicine Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Future Medicine Ltd
Subjects
More information
Scope and Contents
Contents
Recently, the USA FDA has made a labeling change to the drug information contained in carbamazepine. Owing to recent data implicating the HLA allele B*1502 as a marker for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese, the FDA recommends genotyping all Asians for the allele. This allele is seen in high...
Alternative Titles
Full title
Carbamazepine, HLA-B1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2586963
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2586963
Other Identifiers
ISSN
1462-2416
E-ISSN
1744-8042
DOI
10.2217/14622416.9.10.1543
